Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
- Jun 07, 2022 (filed on Jun 07, 2022)Insider Name:Atkinson Katherine CoccaOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
- Jun 07, 2022 (filed on Jun 07, 2022)Insider Name:Atkinson Katherine CoccaOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
- Jun 07, 2022 (filed on Jun 07, 2022)Insider Name:Atkinson Katherine CoccaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
- May 27, 2022 (filed on May 31, 2022)Insider Name:Pelletier Saundra LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:141,000Price:$0.35
- May 04, 2022 (filed on May 06, 2022)Insider Name:O'Brien Anthony StephenOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
- May 04, 2022 (filed on May 06, 2022)Insider Name:Kamdar Kim P.Ownership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
- May 04, 2022 (filed on May 06, 2022)Insider Name:Rutherford ColinOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
- May 04, 2022 (filed on May 06, 2022)Insider Name:Rarick Lisa DaleOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
- May 04, 2022 (filed on May 06, 2022)Insider Name:Greer GillianOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
- Feb 18, 2022 (filed on Feb 23, 2022)Insider Name:Fitzpatrick Alexander AOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
Filings by filing date
- Jun 07, 2022 (filed on Jun 07, 2022)Insider Name:Atkinson Katherine CoccaOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
- Jun 07, 2022 (filed on Jun 07, 2022)Insider Name:Atkinson Katherine CoccaOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
- Jun 07, 2022 (filed on Jun 07, 2022)Insider Name:Atkinson Katherine CoccaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
- May 27, 2022 (filed on May 31, 2022)Insider Name:Pelletier Saundra LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:141,000Price:$0.35
- May 04, 2022 (filed on May 06, 2022)Insider Name:O'Brien Anthony StephenOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
- May 04, 2022 (filed on May 06, 2022)Insider Name:Kamdar Kim P.Ownership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
- May 04, 2022 (filed on May 06, 2022)Insider Name:Rutherford ColinOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
- May 04, 2022 (filed on May 06, 2022)Insider Name:Rarick Lisa DaleOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
- May 04, 2022 (filed on May 06, 2022)Insider Name:Greer GillianOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,000Price:--
- Feb 18, 2022 (filed on Feb 23, 2022)Insider Name:Fitzpatrick Alexander AOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 12400 High Bluff Dr Ste 600 SAN DIEGO CA 92130-3077 |
Tel: | 1-858-5501900 |
Website: | https://www.evofem.com |
IR: | See website |
Key People | ||
Saundra L. Pelletier President, Chief Executive Officer, Director | Justin J. File Chief Financial Officer | Alexander A. Fitzpatrick Executive Vice President, General Counsel, Secretary |
Business Overview |
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. It also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd. |
Financial Overview |
For the three months ended 31 March 2022, Evofem Biosciences Inc revenues increased from $1.1M to $4.3M. Net loss applicable to common stockholders decreased 31% to $32M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Selling & Marketing - Balancing value decrease of 58% to $12.3M (expense). |
Employees: | 119 as of Feb 28, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $137.78M as of Jun 30, 2022 |
Annual revenue (TTM): | $15.57M as of Jun 30, 2022 |
EBITDA (TTM): | -$133.05M as of Jun 30, 2022 |
Net annual income (TTM): | -$282.70M as of Jun 30, 2022 |
Free cash flow (TTM): | -$107.10M as of Jun 30, 2022 |
Net Debt Last Fiscal Year: | $99.62M as of Jun 30, 2022 |
Shares outstanding: | 85,459,214 as of Aug 9, 2022 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |